KAZIA THERAPEUTICS LIMITED (KZIA) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - KAZIA THERAPEUTICS LTD

Financial Performance:

• Current cash position is over $80 million following recent financing.
• Cash runway extends well into 2031, providing significant liquidity for a micro-cap biotech.
• No specific revenue, earnings, or profit margin figures were disclosed as the company is pre-revenue and focused on clinical development.
• No debt or deferred revenue metrics were mentioned in the transcript.

Guidance and Future Outlook:

• 2027 is identified as a primary year for clinical execution and data readouts.
• Completion of the 36-patient Phase 1B trial in Stage 4 Triple Negative Breast Cancer (TNBC) is anticipated by Summer 2027.
• Enrollment for the HR-positive/HER2-negative trial (78 patients) is expected to complete by end of 2027.
• Enrollment for the Phase 2 Colorectal Cancer trial (approx. 90 patients) is targeted for completion by end of 2027.
• Early-stage TNBC trials are planned to initiate in the second half of 2027.
• First Patient In (FPI) for the HR-positive extension is expected by the end of 2026.
• Protein degrader program (PDO1) is targeted for clinic entry by the end of 2027.

Business Segments and Product Lines:

• Lead Asset (Paxalisib): An oral, once-daily dual PI3K/mTOR inhibitor; currently in Phase 1B for TNBC, with expansions into HR-positive breast and Colorectal Cancer (CRC).
• Mechanism of Action: Unique ability to cross the nuclear membrane to impact non-canonical (epigenetic) pathways, reprogramming cancer stem cells and terminally exhausted CD8 T cells, distinct from traditional cytoplasmic PI3K inhibitors.
• Secondary Asset (EVT801): Phase 1 completed; a VEGFR3-specific agent.
• R&D Platforms:
  • DB1: A first-in-class bicyclic peptide targeting chromatin; data expected early 2027.
  • PDO1 (Lead degrader NDL2): A nuclear-based PD-L1 protein degrader; expected to enter clinic by end of 2027.
• Recent Data: In the first six TNBC patients treated with Paxalisib + standard of care, all showed clinical benefit (1 complete metabolic response, 4 partial responses, 1 stable disease) with significant reductions in circulating tumor cells and improved T-cell function.

Market and Competitive Landscape:

• TNBC: Targets high-risk Stage 2B/3 and Stage 4 patients; aims to address recurrence in patients with residual disease after standard surgery, radiation, and chemo.
• HR+ Breast: Differentiating strategy to prevent recurrence in second-line settings (combo with Fulvestrant + CDK4-6), positioning against "me-too" dual PI3K inhibitors by offering superior safety profiles (reduced mucositis/stomatitis) and unique epigenetic effects.
• Colorectal Cancer: Focusing on dMMR/pMMR population (80-85% of cases) where checkpoint inhibitors (e.g., pembrolizumab) have historically failed; Phase 2 includes a monotherapy arm and a pembrolizumab combination arm.
• Competitive Edge: Leveraging the drug's blood-brain barrier penetration capability to access the nuclear compartment, a feature traditional PI3K inhibitors lack.

Risks and Challenges:

• Historical Class Toxicities: Acknowledges that PI3K/mTOR inhibition typically causes hyperglycemia, mucositis, and stomatitis; relies on the hypothesis that low-dose daily regimens will avoid these on-target effects.
• Clinical Trial Timing: Reliance on achieving enrollment milestones by 2027 and demonstrating meaningful clinical data (PFS/OS) in later-stage trials.
• Biomarker Validation: Success depends on validating that the observed biomarker reprogramming (CD8 T-cells, circulating tumor cells) translates directly into improved survival outcomes in larger populations.
• Pipeline Depth: Need to successfully transition early-stage R&D programs (protein degraders) from discovery to clinical trials.

Management Commentary and Tone:

• Confidence: Management expressed strong optimism ("super excited," "knock on wood") regarding the safety profile and the uniqueness of the epigenetic mechanism.
• Strategy: Emphasizes differentiation from class effects and avoiding "fast follower" status by targeting specific unmet needs (recurrence, checkpoint-inhibitor ineligible patients).
• Communication: Indicated a preference for "meaningful" data updates (10-12 patients) rather than incremental updates to provide investor clarity.
• Tone: Professional, forward-looking, and focused on long-term execution and capital efficiency.

Analyst Questions and Answers:

• Question: How does Paxalisib differ from existing PI3K/mTOR inhibitors?
  • Answer: It crosses the nuclear membrane due to its small, lipophilic size (designed for CNS), impacting non-canonical epigenetic pathways and reprogramming cancer stem cells, which other inhibitors cannot do.
• Question: What are the learnings from the original glioblastoma program applied here?
  • Answer: Extensive safety data from 580+ patients provided a robust tolerability profile; the current strategy utilizes lower doses to mitigate traditional toxicity while maintaining efficacy.
• Question: Is there potential for efficacy in PD-L1 negative/low TNBC patients?
  • Answer: Yes; the protocol was amended to include checkpoint-inhibitor ineligible patients (CPS score 1-10), hypothesizing the drug can restore immune system function where pembrolizumab alone fails.
• Question: What are the upcoming catalysts?
  • Answer: Upcoming R&D day in December 2026 (updated preclinical/strategy data), followed by continuous updates throughout 2027, including enrollment completions and early efficacy data across TNBC, HR+, and CRC trials.

Other Key Points:

• R&D Day: Scheduled for December 2nd (2026) to present on the protein degrader platform (PDO1) and other R&D assets.
• Dosage: Paxalisib is being tested at 15mg and 30mg once-daily doses across various indications.
• Combination Therapies: Paxalisib is being evaluated in combination with standard of care (Pembrolizumab + Chemo for TNBC, Fulvestrant + CDK4-6 for HR+, Pembrolizumab for CRC).
• Company Evolution: The company transitioned from a pure neuro-oncology focus (glioblastoma) to a broader oncology platform based on the novel epigenetic mechanism discovered outside of CNS indications.